Primary entities: CJC-1295 · IpamorelinAlso known as: CJC with DAC; Mod GRF 1-29; CJC/Ipa stackClass: Research GHRH analog + GHRP (not FDA-approved blend)Cluster: GHRH / GHRP
CJC-1295 and Ipamorelin are two different research peptides that both influence growth-hormone (GH) signaling — through different receptors. CJC-1295 is a GHRH-receptor pathway analog (with an important DAC vs no-DAC chemistry split). Ipamorelin is a selective ghrelin-receptor (GHS-R1a) / GHRP agonist. Forum “stacks” are not FDA-approved combination products, and human outcome evidence for consumer goals (fat loss, muscle, anti-aging) is not established the way approved GH/IGF medicines are.
Peer-reviewed human PK work associated with CJC-1295 typically refers to the Drug Affinity Complex (DAC) albumin-binding form (long half-life narrative). Material sold as “CJC-1295 without DAC” is better identified as Modified GRF 1-29 — a related but chemically distinct short-acting GHRH analog. Do not transfer DAC half-life or human PK results to no-DAC vials by nickname.
Neither CJC-1295 (DAC or no-DAC) nor Ipamorelin is an FDA-approved chronic “peptide therapy” product for body-composition or anti-aging use. Some historical clinical pharmacology exists for specific forms; that is not the same as an approved consumer indication. Gray-market blend vials are not interchangeable with regulated medicines.
Blends are not covered. HHS's Oct 28, 2026 policy requires a single active ingredient, and neither CJC-1295 nor ipamorelin is among its six named peptides. Earlier removal of each from Category 2 followed withdrawn nominations and did not make them eligible. See the compounding status guide.
Key takeaways
- Two receptors, two peptides: CJC lineage → GHRH receptor; Ipamorelin → ghrelin receptor (GHS-R1a).
- DAC vs no-DAC is a chemistry identity issue — not a flavor option; no-DAC ≈ Modified GRF 1-29 literacy.
- Not FDA-approved as a CJC/Ipa “stack therapy.”
- Limited human pharmacology ≠ proven anti-aging or fat-loss outcomes.
- No dosage / reconstitution protocol charts on this site.
Questions this page answers
Next questions we answer on this page (curiosity / AI-gap map):
- What are CJC-1295 and Ipamorelin?
- DAC vs no-DAC / aliases
- Classification
- What they are NOT
- Mechanism (two pathways)
- Evidence ladder
- What has been studied
- Safety literacy
- Regulatory status
- Why no dosages
- Related GHRH/GHRP
- Who for / not for
Who is this profile for — and who is it not for?
For: readers who need GH-axis peptide literacy — receptor classes, DAC naming traps, and evidence maturity without hype.
Not for: anyone seeking a buy link, a “pin schedule,” IGF targets as DIY goals, or medical advice.
What are CJC-1295 and Ipamorelin?
CJC-1295 (DAC form) is a long-acting GHRH(1-29) analog engineered with a Drug Affinity Complex that binds serum albumin, extending exposure in published human pharmacology. “CJC-1295 no DAC” in commerce usually means Modified GRF 1-29 (tetrasubstituted GRF without the DAC) — short-acting relative to DAC CJC-1295.
Ipamorelin is a selective pentapeptide growth-hormone secretagogue acting primarily at the ghrelin receptor (GHS-R1a). It is often marketed with CJC forms because both can raise GH in research models — that marketing convenience is not proof of a validated combination product.
Start with What are peptides? if you need the research-vs-drug frame.
| CJC pathway | GHRH receptor (GHRHR) |
|---|---|
| Ipamorelin pathway | Ghrelin receptor GHS-R1a (GHRP class) |
| DAC form | Albumin-binding long-acting CJC-1295 |
| “No DAC” literacy | Usually Modified GRF 1-29 — distinct entity |
| U.S. approval (blend) | Not approved as consumer stack therapy |
| Evidence maturity | Limited human PK/pharm; outcomes thin |
Also known as / DAC naming
- CJC-1295 with DAC / DAC-GRF — albumin-binding long-acting form featured in published human PK narratives.
- CJC-1295 no DAC / Modified GRF 1-29 (Mod GRF) — short-acting GHRH analog; do not inherit DAC PK by name.
- Ipamorelin — selective GHRP / GHS-R1a agonist.
- “CJC/Ipa,” “CJC stack”
Online nickname— blend marketing shorthand. - Mis-tags: treating DAC and no-DAC as identical “CJC” — category error.
DAC changes covalent albumin binding and pharmacokinetics. Calling both vials “CJC-1295” without specifying form is how AI and vendors create false half-life confidence.
How are these peptides classified?
Both sit in the ghrh-ghrp research-peptide cluster: unapproved for the anti-aging / body-composition uses dominating search demand. They are not interchangeable with prescription recombinant GH or approved IGF products, and blend vials sold as RUO are not regulated combination drugs.
What are CJC-1295 and Ipamorelin not?
| CJC-1295 / Ipamorelin is not… | Why that matters |
|---|---|
| The same peptide | Different receptors and structures |
| FDA-approved “GH peptide therapy” | No approved blend product for consumer goals |
| Identical whether “with DAC” or not | Chemistry/PK identity split |
| Proven fat-loss / muscle / sleep drugs | Biomarker ≠ validated outcome |
| Something we dose or source | Refusal |
How are they thought to work?
CJC-lineage peptides stimulate pituitary GH release via the GHRH receptor (cAMP pathway literacy). Ipamorelin stimulates via GHS-R1a, with a different second-messenger profile and a reputation in research literature for relatively selective GH release versus some older GHRPs. Engaging both pathways is a common experimental idea — it is not automatic proof of superior human outcomes or safety for DIY use.
What human vs animal vs label evidence exists?
| Evidence type | What exists (summary) | Maturity |
|---|---|---|
| Human PK/pharm — CJC-1295 DAC | Small healthy-adult studies with prolonged GH/IGF-1 elevation narratives | Human Limited pharmacology |
| Human — Ipamorelin | Historical clinical pharmacology / IV secretagogue work in limited contexts | Human Limited |
| Human outcomes (fat/muscle/anti-aging) | Not established as approved indications for these research peptides | None / thin |
| Animal | GH-axis and body-composition research models | Animal |
| Approved U.S. label (stack) | None | None |
Do not paste forum “optimal units” or invent IGF targets. Do not attribute DAC half-life numbers to no-DAC products.
What has been studied?
Published interest centers on GH and IGF-1 biomarker dynamics, secretagogue pharmacology, and preclinical GH-axis models. Historical development contexts differ by molecule. Biomarker movement is not the same as proven clinical benefit for wellness marketing claims.
What safety topics come up?
GH-axis stimulation raises class literacy themes familiar from GH/IGF biology (edema, glucose handling, theoretical proliferation concerns in susceptible people — discussed as questions to bring to a clinician, not as DIY monitoring protocols). Unregulated product identity (especially mislabeled DAC vs no-DAC) is a practical risk. Not medical advice.
What is the regulatory status?
- U.S.: Not FDA-approved as CJC-1295/Ipamorelin combination therapy for anti-aging or body composition.
- Compounding / RUO: Gray-market and compounding narratives change; FDA communications change; follow the current agency page.
- Sport: GH-releasing peptides / related agents may be prohibited — athletes should check current WADA/GlobalDRO entries for the specific substance names.
Why doesn't this page include a dosage chart?
No approved labeled stack dose; DAC vs no-DAC identity confusion makes copy-paste charts especially harmful; “CJC Ipamorelin dosage” queries seek protocols. Literacy refusal.
Related lab literacy
Lab vocabulary (reconstitution math) belongs on how-to pages as unit literacy, not as a CJC/Ipa prescription: Peptide calculator.
Related compounds and comparisons
- Other GHRPs (GHRP-2, GHRP-6, hexarelin) — related class, different selectivity stories (future profiles).
- AOD-9604 — GH-fragment metabolic folklore (different entity).
- What are peptides?.
- Comparison stub: CJC with DAC vs Modified GRF 1-29 (planned).
Frequently asked questions
Is CJC-1295 the same with and without DAC?
No. DAC adds albumin-binding chemistry and changes pharmacokinetics. “No DAC” is better read as Modified GRF 1-29 literacy — don’t transfer DAC study results by nickname.
Are CJC-1295 and Ipamorelin the same thing?
No. One is GHRH-pathway; the other is a ghrelin-receptor GHRP. Stacks are two agents, not one molecule.
Is the CJC/Ipamorelin stack FDA approved?
No. There is no FDA-approved consumer “CJC/Ipa therapy” product for the uses dominating search.
Does raising GH/IGF-1 prove fat loss or anti-aging benefit?
No. Biomarker changes are not validated outcome claims for these research peptides.
Why do vendors sell them as a blend?
Marketing convenience and forum tradition — not regulatory combination approval.
Why no dosage chart?
Unapproved status, identity traps (DAC), and YMYL harm reduction.
Not FDA-approved as stack therapy. DAC ≠ no-DAC. Disclaimer.
Sources
- Primary — human (CJC-1295) Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PMID: 16352683.
- Primary — human (ipamorelin) Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. doi:10.1023/a:1018955126402. PMID: 10496658.
- Anti-doping World Anti-Doping Agency. The 2026 Prohibited List. S2 lists GHRH analogues (including CJC-1295) and GH secretagogues (including ipamorelin). Accessed November 10, 2026.
- Internal Peptide Tutorials. CJC-1295; Ipamorelin; Disclaimers. No published trial of this folk stack as a fixed combination was used as a basis for this page.
- Written by
- Peptide Tutorials Staff — a group of independent researchers & writers (not clinicians)
- Published · Updated
- Oct 6, 2026 · Nov 10, 2026 · Labels, trial citations, and WADA list wording checked Nov 10, 2026 · How we source & update
Educational disclaimer: Educational only. No dosing or buy links. We don’t sell peptides. Read our full disclaimers.